Recent Updates
Recently added Catalysts
INKT Positive Sentiment

MiNK Therapeutics to Participate in HC Wainwright Cell Therapy Virtual Conference

Thursday, February 16, 2023 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: MiNK Therapeutics, a clinical-stage biopharmaceutical company, announced that its President and CEO, Dr. Jennifer Buell, will participate in a fireside chat at the HC Wainwright Cell Therapy Virtual Conference scheduled for February 28th. This event underscores MiNK's focus on allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies for cancer and immune-mediated diseases. Access to the live chat will be available online, with a replay accessible on the company's website afterward.
Price reaction · baseline $20.101 (2023-02-15 close) · hit after-hours · clean, no other INKT news in the window
day 0 close
+4.5%
day 1
+5%
day 3
-0.5%

Market Sentiment Analysis

POSITIVE FACTORS

  • MiNK Therapeutics is actively participating in a significant industry conference.
  • Dr. Jennifer Buell's involvement highlights the company’s leadership and visibility in the field of cell therapies.
  • The participation demonstrates MiNK's commitment to advancing its innovative therapeutic approaches.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+38%
120-day peak, hindsight
Typical move
6%
average across 2 past catalysts
Cash runway
~11 mo
Medium dilution risk

Full Press Release Details

NEW YORK, Feb. 16, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, announced that Dr. Jennifer Buell, President and CEO of MiNK, will participate in a fireside chat at the HC Wainwright Cell Therapy Virtual Conference on February 28th, at 9:00 AM ET.
Access to the live fireside chat is available at https://journey.ct.events/view/1c9dcd6c-cb2c-46d1-a01f-63352600ea5c. Following the fireside chat, a replay will be available on the Events and Presentations page of the MiNK website at https://investor.minktherapeutics.com/events-and-presentations.
About MiNK Therapeutics

Frequently Asked Questions

What is MiNK Therapeutics known for?

MiNK Therapeutics focuses on developing allogeneic, off-the-shelf iNKT cell therapies.

When is Dr. Jennifer Buell's fireside chat scheduled?

Dr. Buell's fireside chat is set for February 28, 2023, at 9:00 AM ET.

How can I access the live fireside chat?

The live fireside chat can be accessed at a specific event link provided.

Where can I find the replay of the chat?

A replay will be available on the Events and Presentations page of MiNK's website.

What type of diseases does MiNK’s therapy aim to treat?

MiNK Therapeutics aims to treat cancer and other immune-mediated diseases.

ShareAdd on Google
Tags: INKT MiNK Therapeutics iNKT cell therapies clinical-stage HC Wainwright cancer therapies
Last updated: Feb 16, 2023

Biotech snapshot

Cash runway
$9M liquidity · $1M/mo burn
~11 mo
Medium dilution risk

Catalyst track record

+38%
best trade around INKT's last catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for INKT.

See every catalyst's timing & PoA →